David C Fajgenbaum Selected Research

Castleman Disease (Castleman's Disease)

4/2022	Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review.
1/2022	Transcriptome and unique cytokine microenvironment of Castleman disease.
1/2022	Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
1/2022	Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO.
1/2022	Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy.
12/2021	UCD with MCD-like inflammatory state: surgical excision is highly effective.
10/2021	Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.
9/2021	TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy.
3/2021	Emerging role of 18F-FDG PET/CT in Castleman disease: a review.
1/2021	Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David C Fajgenbaum Research Topics

Disease

21	Castleman Disease (Castleman's Disease) 04/2022 - 12/2015
16	Thrombocytopenia (Thrombopenia) 04/2022 - 02/2016
15	Edema (Dropsy) 04/2022 - 02/2016
14	Fever (Fevers) 04/2022 - 02/2016
11	Cytokine Release Syndrome 12/2021 - 05/2014
10	Fibrosis (Cirrhosis) 04/2022 - 02/2016
8	Inflammation (Inflammations) 01/2022 - 11/2018
7	Lymphadenopathy 04/2022 - 04/2016
7	Multi-centric Castleman's Disease 10/2021 - 05/2014
6	Cytopenia 04/2022 - 03/2017
4	Thrombocytosis (Thrombocythemia) 04/2022 - 03/2017
4	Primary Myelofibrosis (Myelosclerosis) 01/2022 - 05/2017
3	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 04/2022 - 01/2019
3	Anemia 01/2022 - 03/2017
3	Neoplasms (Cancer) 01/2022 - 01/2020
3	COVID-19 01/2022 - 01/2020
3	Ascites 11/2021 - 04/2016
3	Rare Diseases (Rare Disease) 11/2019 - 12/2015
2	Hypergammaglobulinemia (Hyperimmunoglobulinemia) 04/2022 - 03/2017
2	Hypoalbuminemia 01/2022 - 03/2017
2	Autoimmune Lymphoproliferative Syndrome 01/2022 - 01/2020
2	Renal Insufficiency (Renal Failure) 10/2021 - 01/2017
1	Hyperplasia 04/2022
1	Primary Effusion Lymphoma 11/2021
1	Kaposi Sarcoma (Kaposi's Sarcoma) 11/2021
1	POEMS Syndrome (Syndrome, POEMS) 11/2021
1	Communicable Diseases (Infectious Diseases) 10/2021
1	Leukocytosis (Pleocytosis) 02/2020
1	Hypersensitivity (Allergy) 01/2020
1	Histiocytosis 01/2020
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2019
1	Hodgkin Disease (Hodgkin's Disease) 01/2019
1	Disease Progression 01/2018
1	Interstitial Lung Diseases (Interstitial Lung Disease) 03/2017
1	Proteinuria 03/2017
1	Hepatomegaly 04/2016
1	Splenomegaly 04/2016
1	Acute Kidney Injury (Acute Renal Failure) 02/2016
1	Abdominal Pain (Pain, Abdominal) 02/2016
1	Paraneoplastic Syndromes (Paraneoplastic Syndrome) 05/2014

Drug/Important Bio-Agent (IBA)

14	Reticulin (Reticular Fiber)IBA 04/2022 - 02/2016
13	Interleukin-6 (Interleukin 6)IBA 04/2022 - 05/2014
9	CytokinesIBA 04/2022 - 05/2014
5	C-Reactive ProteinIBA 04/2022 - 04/2016
3	siltuximabIBA 01/2022 - 01/2016
2	AntibodiesIBA 01/2022 - 01/2017
2	Sirolimus (Rapamycin)FDA Link 01/2022 - 01/2020
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021 - 04/2016
2	AutoantibodiesIBA 01/2021 - 05/2014
2	Immunoglobulins (Immunoglobulin)IBA 01/2018 - 05/2017
1	Immunoglobulin G (IgG)IBA 01/2022
1	Neutralizing AntibodiesIBA 01/2022
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2022
1	Interferon Type IIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 12/2021
1	InterleukinsIBA 09/2021
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 03/2021
1	AA amyloidosisIBA 02/2020
1	CreatinineIBA 02/2020
1	Interleukin-3 (Interleukin 3)IBA 01/2020
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020
1	Phosphotransferases (Kinase)IBA 01/2020
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020
1	Pharmaceutical PreparationsIBA 11/2019
1	Prednisone (Sone)FDA LinkGeneric 01/2019
1	Biological ProductsIBA 01/2019
1	RNA (Ribonucleic Acid)IBA 01/2019
1	Formaldehyde (Formol)FDA Link 01/2019
1	Thalidomide (Thalomid)FDA Link 01/2019
1	Monoclonal AntibodiesIBA 01/2019
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019
1	ParaffinIBA 01/2019
1	Rituximab (Mabthera)FDA Link 09/2018
1	ChemokinesIBA 01/2018
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2016
1	Interleukin-2 Receptors (IL 2 Receptor)IBA 04/2016
1	Alkaline PhosphataseIBA 02/2016
1	NexusIBA 01/2016
1	4- Acetamido- 4'- isothiocyanatostilbene- 2,2'- disulfonic Acid (SITS)IBA 01/2016

Therapy/Procedure

7	Therapeutics 01/2022 - 05/2014
2	Precision Medicine 01/2019 - 12/2015
1	Immunomodulation 01/2021
1	Drug Therapy (Chemotherapy) 04/2016